SpliceBio announces first patient dosed in Phase 1/2 ASTRA study of SB-007, a dual-AAV gene therapy for Stargardt disease SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced that it has dosed the first patient in its Phase 1/2 ASTRA study of SB-007. SpliceBio’s dual […]
Ottimo Pharma, a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, on Thursday announced the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and […]
Congratulations to Renée Aguiar-Lucander, who won the prestigious Executive of the Year Award – Commercial Stage Companies at the Scrip Awards 2024 As the awards celebrated their 20th anniversary, Renée came top from a list of finalists representing the very best in the biotech industry. Renée led the company through clinical development of Tarpeyo (budesonide), […]
